SCHEMBL26038580

SCHEMBL26038580

O=Cc1nc(O)c2scc(-c3ccccn3)c2n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KRAS P01116 2/20 0.36
BRD4 O60885 1/20 0.36
BRD2 P25440 1/20 0.36
BRD3 Q15059 1/20 0.36
BAZ2B Q9UIF8 1/20 0.36
BAZ2A Q9UIF9 1/20 0.36
CYP19A1 P11511 1/20 0.35
PDE10A Q9Y233 1/20 0.35
ADORA3 P0DMS8 2/20 0.35
KDM4A O75164 1/20 0.35
KDM4B O94953 1/20 0.35
KDM5B Q9UGL1 1/20 0.35
NR4A1 P22736 1/20 0.35
VCP P55072 1/20 0.35
CSNK2A1 P68400 1/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
HTR2B P41595 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20665754 0.81 KDM4E (0.49) CYP19A1PDE10AADORA3KDM4AKDM4B
SCHEMBL26038568 0.81 BRD4 (0.43) KRASBRD4BRD2BRD3BAZ2B
SCHEMBL26038698 0.80 PDE10A (0.44) KRASCYP19A1PDE10AADORA3NR4A1
SCHEMBL29720521 0.79 CSNK2A1 (0.43) KRASBRD4BRD2BRD3BAZ2B
SCHEMBL26042492 0.79 CSNK2A1 (0.43) KRASBRD4BRD2BRD3BAZ2B
SCHEMBL24128068 0.78 IKBKB (0.41) KRASBRD4BRD2BRD3BAZ2B
SCHEMBL24128144 0.75 ADORA3 (0.35) KRASBRD4BRD2BRD3BAZ2B
SCHEMBL24128157 0.73 KDM4E (0.41) CYP19A1PDE10AADORA3KDM4AKDM4B
SCHEMBL29720643 0.73 KDM4E (0.41) CYP19A1PDE10AADORA3KDM4AKDM4B
SCHEMBL24128111 0.73 ADORA3 (0.47) ADORA3KDM4AKDM4BKDM5BCSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227466-A1 SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE SHY THERAPEUTICS, LLC 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227466-A1 SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE KRAS, G3BP1, NRAS KRAS 1/4885BRD4 885/4885BRD2 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.